Dbv Technologies SA（DBVT）资讯与事件DBVTDbv Technologies SA

DBV Technologies Submits BLA for Viaskin Peanut Patch to FDA

DBV Technologies announced that the company has submitted a Biologics License Application to the U.S. FDA for the Viaskin Peanut Patch in children with peanut allergy aged 4 through 7 years. DBV has requested Priority Review of the BLA. The FDA previously granted Breakthrough Therapy Designation to the Viaskin Peanut Patch.

DBV Technologies Issues New Shares Raising Approximately $50M

DBV Technologies announced that, pursuant to the company's At-The-Market Program established on September 1, 2025 and included in a new registration statement and accompanying prospectus filed on July 27, it has agreed to issue and sell new ordinary shares in the form of American Depositary Shares, for total gross proceeds to the company of approximately $50M, before deducting sales agent commissions and offering expenses payable by the company, to RA Capital Management, L.P through Citizens JMP Securities acting as sales agent. Each ADS represents the right to receive five ordinary shares of the company.

DBV Technologies Files $150M Securities Registration Statement

DBV Technologies announced that it has filed a new automatically effective shelf registration statement with the SEC, which includes a base prospectus and a sales agreement prospectus supplement refreshing the company's previously established at-the-market offering program by filing a prospectus supplement for sales of up to $150M of American Depositary Shares. The company intends to use the net proceeds of any offering of securities primarily for activities associated with manufacturing expansion, our BLAs in ages 4 through 7 and 1 through 3, launch preparation of Viaskin Peanut in ages 4-7, if approved, development of its product candidates, and for working capital and other general corporate purposes. Accordingly, The company will have significant discretion in the use of any net proceeds.